Analysts expect Insulet Co. (NASDAQ:PODD) to post earnings per share of $0.03 for the current fiscal quarter, Zacks Investment Research reports. Eight analysts have issued estimates for Insulet’s earnings. The highest EPS estimate is $0.06 and the lowest is ($0.04). Insulet reported earnings per share of ($0.04) during the same quarter last year, which would indicate a positive year over year growth rate of 175%. The company is expected to announce its next earnings report after the market closes on Thursday, November 1st.
According to Zacks, analysts expect that Insulet will report full-year earnings of ($0.09) per share for the current financial year, with EPS estimates ranging from ($0.23) to ($0.01). For the next fiscal year, analysts anticipate that the company will report earnings of $0.36 per share, with EPS estimates ranging from $0.13 to $0.61. Zacks Investment Research’s earnings per share averages are an average based on a survey of analysts that cover Insulet.
Insulet (NASDAQ:PODD) last released its quarterly earnings data on Thursday, August 2nd. The medical instruments supplier reported ($0.03) EPS for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.10. The company had revenue of $124.26 million during the quarter, compared to the consensus estimate of $132.89 million. Insulet had a negative net margin of 3.47% and a negative return on equity of 11.91%. The firm’s revenue for the quarter was up 13.2% compared to the same quarter last year. During the same period last year, the firm earned ($0.13) EPS.
PODD has been the subject of a number of analyst reports. Leerink Swann reaffirmed an “outperform” rating and set a $130.00 price objective on shares of Insulet in a report on Tuesday, September 11th. BidaskClub downgraded shares of Insulet from a “strong-buy” rating to a “buy” rating in a report on Tuesday, June 19th. Zacks Investment Research raised shares of Insulet from a “hold” rating to a “buy” rating and set a $119.00 price objective for the company in a report on Monday, October 1st. Morgan Stanley raised their price objective on shares of Insulet from $96.00 to $105.00 and gave the stock an “equal weight” rating in a report on Thursday. Finally, Oppenheimer set a $96.00 target price on shares of Insulet and gave the stock a “hold” rating in a research report on Friday, August 3rd. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, twelve have assigned a buy rating and two have assigned a strong buy rating to the company. The stock has an average rating of “Buy” and an average target price of $99.13.
Shares of NASDAQ:PODD traded up $0.75 during midday trading on Wednesday, reaching $89.30. 10,003 shares of the company’s stock were exchanged, compared to its average volume of 581,970. The company has a market capitalization of $6.25 billion, a price-to-earnings ratio of -191.67 and a beta of 1.56. Insulet has a 12 month low of $56.62 and a 12 month high of $108.90. The company has a debt-to-equity ratio of 3.22, a quick ratio of 5.01 and a current ratio of 5.54.
In other Insulet news, EVP Aiman Abdel-Malek sold 602 shares of the firm’s stock in a transaction dated Tuesday, August 14th. The shares were sold at an average price of $86.60, for a total value of $52,133.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Shacey Petrovic sold 960 shares of the firm’s stock in a transaction dated Tuesday, September 4th. The shares were sold at an average price of $104.26, for a total transaction of $100,089.60. The disclosure for this sale can be found here. Insiders have sold a total of 7,207 shares of company stock valued at $651,334 in the last quarter. 3.60% of the stock is currently owned by corporate insiders.
Institutional investors and hedge funds have recently bought and sold shares of the business. Pier 88 Investment Partners LLC acquired a new stake in Insulet in the 2nd quarter valued at about $184,000. First Republic Investment Management Inc. acquired a new stake in Insulet in the 1st quarter valued at about $209,000. Harbour Capital Advisors LLC acquired a new stake in Insulet in the 2nd quarter valued at about $269,000. LPL Financial LLC acquired a new stake in Insulet in the 1st quarter valued at about $276,000. Finally, AMP Capital Investors Ltd acquired a new stake in Insulet in the 2nd quarter valued at about $274,000.
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod Insulin Management System (Omnipod System), which consists of an easy-to-use continuous insulin delivery system; and Personal Diabetes Manager, a handheld wireless device.
Recommended Story: How Short Selling Works
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.